ArticleScientific reports2023
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Nanoparticle-Hydrogel Composites for Precision Medicine.Cell biomaterials · 2026Article
- Hydrogel-Mediated Delivery of Drug Nanocarriers in the Oedematous Postoperative Brain.Pharmaceutical research · 2026Article
- Local delivery of Doxorubicin and Olaparib loaded injectable hydrogels with adjuvant radiotherapy improves survival in a glioblastoma in vivo model.Drug delivery and translational research · 2026Article
- Hydrogel-mediated tri-modal nanoplatform for localized colorectal cancer therapy via smart chemo-photothermal-radiotherapy.Journal of biological engineering · 2026Article
- Local Nanomedicine and Nano-Enabled Biomaterials After Glioblastoma Resection.International journal of nanomedicine · 2026Review
- Oleuropein- and hydroxytyrosol-loaded nanoparticles: a novel strategy against glioblastoma aggressiveness.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeted amplification of alternating electric fields using ferroelectric nanoparticles.npj biomedical innovations · 2025Article
- Preparation and evaluation of temozolomide loaded PLGA nanoparticles for the treatment of glioblastoma multiforme.Scientific reports · 2025Article
- MiR-7 inhibits progression of glioblastoma by impairing autophagy resolution, energy metabolism and ECM remodeling.Journal of experimental & clinical cancer research : CR · 2025Article
- Targeting the glioblastoma resection margin with locoregional nanotechnologies.Nature reviews. Clinical oncology · 2025Review
- Nanoparticles for Glioblastoma Treatment.Pharmaceutics · 2025Review
- Optimizing Therapeutics for Intratumoral Cancer Treatments: Antiproliferative Vanadium Complexes in Glioblastoma.International journal of molecular sciences · 2025Article
- Nanotechnology-driven strategies in postoperative cancer treatment: innovations in drug delivery systems.Frontiers in pharmacology · 2025Review
- Nanofibers in Glioma Therapy: Advances, Applications, and Overcoming Challenges.International journal of nanomedicine · 2025Review
- Chemotherapeutic nanoparticles for glioblastoma.Frontiers in oncology · 2025Review
- Magnet-Guided Temozolomide and Ferucarbotran Loaded Nanoparticles to Enhance Therapeutic Efficacy in Glioma Model.Nanomaterials (Basel, Switzerland) · 2024Article
- Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel.Molecular medicine reports · 2023Article
- Overcoming challenges in glioblastoma treatment: targeting infiltrating cancer cells and harnessing the tumor microenvironment.Frontiers in cellular neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
Malignant gliomas are a type of primary brain tumour that originates in glial cells. Among them, glioblastoma multiforme (GBM) is the most common and the most aggressive brain tumour in adults, classified as grade IV by the World Health Organization. The standard care for GBM, known as the Stupp protocol includes surgical resection followed by oral chemotherapy with temozolomide (TMZ). This treatment option provides a median survival prognosis of only 16-18 months to patients mainly due to tumour recurrence. Therefore, enhanced treatment options are urgently needed for this disease. Here we show the development, characterization, and in vitro and in vivo evaluation of a new composite material for local therapy of GBM post-surgery. We developed responsive nanoparticles that were loaded with paclitaxel (PTX), and that showed penetration in 3D spheroids and cell internalization. These nanoparticles were found to be cytotoxic in 2D (U-87 cells) and 3D (U-87 spheroids) models of GBM. The incorporation of these nanoparticles into a hydrogel facilitates their sustained release in time. Moreover, the formulation of this hydrogel containing PTX-loaded responsive nanoparticles and free TMZ was able to delay tumour recurrence in vivo after resection surgery. Therefore, our formulation represents a promising approach to develop combined local therapies against GBM using injectable hydrogels containing nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.